GLP-1 drugs are reshaping cravings, impulse eating and reward-driven snacking, forcing food manufacturers to rethink indulgence, functionality and the future of emotional eating.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.